Ubiquitin-Dependent Modification of Skeletal Muscle by the Parasitic Nematode, Trichinella spiralis by White, RR et al.
1 
Title: Ubiquitin-dependent modification of skeletal muscle by the parasitic nematode, 1 
Trichinella spiralis. 2 
Short Title: Secretion of a Ub E2 enzyme by a parasitic worm 3 
  4 
Authors: 5 
White RR1, Ponsford AH2, Weekes MP3,4, Rodrigues R4, Ascher DB5,6, Mol M7, Selkirk 6 
ME1, Gygi SP4, Sanderson CM2, Artavanis-Tsakonas K7* 7 
  8 
Affiliations: 9 
1 Department of Life Sciences, Imperial College London, UK 10 
2 Department of Cellular and Molecular Physiology, Institute of Translational Medicine, 11 
University of Liverpool 12 
3Cambridge Institute for Medical Research, University of Cambridge, UK 13 
4 Department of Cell Biology, Harvard Medical School, Boston 14 
5 Department of Biochemistry, University of Cambridge, UK 15 
6 Department of Biochemistry, University of Melbourne, Australia 16 
7 Department of Pathology, University of Cambridge, UK 17 
  18 
Contact Information: 19 
*ka447@cam.ac.uk 20 
  21 
Abstract: 22 
Trichinella spiralis is a muscle-specific parasitic worm that is uniquely intracellular. T. 23 
spiralis reprograms terminally differentiated skeletal muscle cells causing them to de-24 
differentiate and re-enter the cell cycle, a process that cannot occur naturally in 25 
mammalian skeletal muscle cells, but one that holds great therapeutic potential. 26 
2 
Although the host ubiquitin pathway is a common target for viruses and bacteria during 27 
infection, its role in parasite pathogenesis has been largely overlooked. Here we 28 
demonstrate that the secreted proteins of T. spiralis contain E2 Ub-conjugating and E3 29 
Ub-ligase activity. The E2 activity is attributed to TsUBE2L3, a novel and conserved T. 30 
spiralis enzyme located in the secretory organ of the parasite during the muscle stages 31 
of infection. TsUBE2L3 cannot function with any T.spiralis secreted E3, but specifically 32 
binds to a panel of human RING E3 ligases, including the RBR E3 ARIH2 with which it 33 
interacts with a higher affinity than the mammalian ortholog UbcH7/UBE2L3. Expression 34 
of TsUBE2L3 in skeletal muscle cells causes a global downregulation in protein 35 
ubiquitination, most predominantly affecting motor, sarcomeric and extracellular matrix 36 
proteins, thus mediating their stabilization with regards to proteasomal degradation. This 37 
effect is not observed in the presence of the mammalian ortholog, suggesting functional 38 
divergence in the evolution of the parasite protein. These findings demonstrate the first 39 
example of host-parasite interactions via a parasite-derived Ub conjugating enzyme; an 40 
E2 that demonstrates a novel muscle protein stabilization function. 41 
  42 
Author Summary 43 
Parasitic worms often establish long-lasting infections in their hosts; tightly regulating 44 
their surroundings to strike a delicate balance between host cell modulation and 45 
protection that will ensure their replication. This is accomplished via the active secretion 46 
of parasite glycolipids and glycoproteins into the host. Trichinella spiralis, a parasitic 47 
nematode that infects skeletal muscle of mammals, birds and reptiles, is the only 48 
parasitic worm with a true intracellular stage. T. spiralis invade terminally differentiated 49 
myotubes, reprogramming them to de-differentiate and re-enter the cell cycle, a process 50 
that cannot occur naturally in mammalian skeletal muscle cells, but one that holds great 51 
therapeutic potential. We have identified and characterized a novel T. spiralis secreted 52 
3 
protein that, despite a high level of sequence identity, appears to have evolved a 53 
different function to its host ortholog. This protein is an active Ub conjugating enzyme 54 
that binds to a panel of human E3 Ub ligases with higher affinity than the host ortholog. 55 
Furthermore, when expressed in skeletal muscle cells in culture, its presence uniquely 56 
leads to the stabilization of muscle-specific proteins via the downregulation of their 57 
ubiquitination. 58 
  59 
Introduction 60 
The ubiquitin (Ub) pathway is essential for post-translational protein regulation in 61 
eukaryotic cells, controlling many important cellular processes such as transcription, cell 62 
cycle, differentiation and apoptosis ([1,2]. Ub is a 76 amino acid protein that, in a highly 63 
regulated fashion, is covalently conjugated to substrate proteins via an E1 activating, E2 64 
conjugating and E3 ligating enzyme cascade[3]. Ubiquitination regulates the fate and 65 
function of the substrate, to maintain a healthy homeostasis within the cell. The 66 
particular outcome is determined by a combination of possible variables, for example the 67 
specific lysine residue attachment site on the protein, the length and type of Ub chain, 68 
and the number of total Ub moieties on a single protein[4,5]. Since the specific E2:E3 69 
enzyme pair denotes substrate and moiety specificity, ubiquitination is highly regulated 70 
by the abundance, localization and activity of these Ub-specific enzymes. 71 
  72 
Considering the important role of the Ub pathway in maintaining the healthy homeostasis 73 
of a cell, and therefore the healthy physiology of an organism, it is not surprising that its 74 
disruption is directly implicated in infection and disease. Prokaryotes do not have an 75 
endogenous Ub pathway, however certain viral and bacterial pathogens encode Ub-76 
specific enzymes that target host Ub machinery for enhanced virulence and immune 77 
evasion[6–9]. Although much attention has been aimed at understanding the role of the 78 
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Ub pathway in infection by pathogenic viruses and bacteria, very little is known about 79 
how parasites may interfere with host ubiquitination. Parasites are eukaryotic and 80 
therefore already express endogenous Ub machinery. To date, there are only two 81 
reports of the direct targeting of the host Ub pathway during parasitic infection. The first 82 
involves indirect communication with the host Ub system by the Toxoplasma dense 83 
granule protein GRA16. GRA16 is exported into the host cell nucleus and binds the host 84 
Ub hydrolase HAUSP, modulating the cell cycle via HAUSP-dependent p53 85 
regulation[10,11]. The second involves direct communication with the host Ub pathway 86 
by a Trypanosoma cruzi active RING domain secretory protein SPRING. Hashimoto et al 87 
showed that in vitro, SPRING is able to catalyze Ub conjugation with human UbcH5 and 88 
13. 89 
  90 
Trichinella spiralis is a promiscuous parasitic nematode that infects skeletal muscle cells 91 
of mammals, birds and reptiles. The parasite is propagated by the consumption of 92 
infected tissue and undergoes the same life cycle stages irrespective of the host. The 93 
longest life cycle stage is intracellular, giving the parasite direct access to host 94 
intracellular machinery. The severity of the associated disease, trichinellosis, depends 95 
on the infection load and the presentation varies in severity correspondingly from 96 
asymptomatic to fatal. During the chronic intracellular phase of infection, T. spiralis 97 
invade terminally differentiated (TD) myotubes, releasing a mixture of secreted products 98 
(SP) including glycoproteins and glycolipids into the cytoplasm and nucleus of the host 99 
cell. The host cell undergoes a dramatic program of de-differentiation and cell cycle re-100 
entry followed by cell cycle arrest, initiated and characterized by a change in 101 
transcriptional profile, a downregulation of host muscle specific proteins such as 102 
myogenin and myosin heavy chain and the loss of identity and function as a 103 
myotube[12,13]. This coincides with a change in morphology, as the cell is transformed 104 
5 
from a long, linear fiber into a fat, oval-shaped structure termed a nurse cell ([14–16]. 105 
The parasite resides inside the nurse cell until a chance transmission occurs. It is 106 
thought that this process of nurse cell development is induced by the T. spiralis SP via 107 
direct communication with host cell proteins and genetic material. 108 
  109 
In this study we used muscle-stage T. spiralis as a model to investigate whether 110 
eukaryotic parasites have evolved strategies to target the Ub pathway during infection. 111 
Not only does T. spiralis SP contain both E2 Ub conjugating and E3 Ub ligase activity, 112 
we were able to attribute the E2 activity to the secretion of TsUBE2L3, an enzyme that is 113 
located in the secretory organ of T. spiralis during infection. We show that TsUBE2L3 114 
interacts with the host E3 ARIH2 with higher binding affinity than the endogenous 115 
mammalian ortholog. Furthermore, TsUBE2L3 causes a significant downregulation in 116 
the levels of ubiquitination of motor, sarcomeric and extracellular matrix proteins. These 117 
findings demonstrate the first example of host-parasite interaction via a parasite-derived 118 
Ub conjugating enzyme that can stabilize skeletal muscle-specific proteins by inhibiting 119 
their ubiquitination. 120 
  121 
 122 
  123 
Results 124 
  125 
Intracellular-stage T. spiralis secreted products (SP) demonstrate Ub conjugation 126 
and ligation activities 127 
An in vitro Ub conjugation assay was carried out to determine if the secreted products 128 
(SP) of T. spiralis muscle larvae contain E1, E2 or E3 enzymatic activity. All reactions 129 
were separated by SDS-PAGE and analyzed by streptavidin blot (Figure 1A). As a 130 
6 
positive control, a reaction containing human recombinant E1 (HsUBE1A), human 131 
recombinant E2 (HsUBE2L3), and human recombinant E3 (parkin) was analyzed. In the 132 
presence of HsUBE2L3, parkin (51 kDa) was able to auto-ubiquitinate, visible as a 133 
streptavidin-reactive smear (Figure 1A). When HsUBE2L3 was removed from the 134 
reaction no signal was observed (b), confirming the requirement of the E2 for parkin 135 
auto-ubiquitination. T. spiralis SP were then substituted into the reaction for either the 136 
E2, E3 or E1. A reaction containing T. spiralis SP plus HsUBE1A only was also 137 
analyzed, as well as a reaction containing only T. spiralis SP and biotin-Ub as a negative 138 
control. A streptavidin-reactive smear, representing either parkin-Ub or SP-Ub, was 139 
observed when T. spiralis SP were substituted in the place of HsUBE2L3. Signal 140 
representing SP-Ub was also observed when T. spiralis SP were substituted in the place 141 
of parkin. No ubiquitination was observed when T. spiralis SP were substituted in the 142 
place of HsUBE1A, or when the E1 and SP were reacted alone. This suggests that 143 
proteins in T. spiralis SP have E2 and E3 but not E1 activities. Since these proteins are 144 
activated only by the addition of the human E1 plus E2, or the human E1 plus E3, it is 145 
unlikely that the T. spiralis secreted E2 and E3 can work together without an external 146 
enzyme source. It was therefore hypothesized that ubiquitination of substrates by T. 147 
spiralis muscle larvae SP requires mammalian host E2 or E3 partners. 148 
  149 
Proteomic analysis of T. spiralis SP identifies a Ub conjugating enzyme, 150 
TsUBE2L3 151 
Purified SP were separated by SDS-PAGE and visualised using colloidal-coomassie 152 
staining (Figure 1B) prior to manual excision and analysis by LC/MS/MS. Data was then 153 
searched against the T. spiralis UniProt proteome, its reverse complement, common 154 
contaminants of SDS-PAGE and mass spectrometry as well as the rat UniProt 155 
proteome. Less than 1% of the protein matches were rat proteins. To validate the data, 156 
7 
the experiment was repeated. Peptides from both the first and second experiment were 157 
combined and assembled into proteins. The data was cross-referenced with a previous 158 
study of the T. spiralis secretome by Robinson et al. identifying all the same proteins, 159 
plus many new ones[17–19]. Proteins previously identified in T. spiralis SP using 160 
alternative methods were also present amongst the results[20–25]). To avoid 161 
contamination with proteins released from dead or dying parasites, uncoiled and floating 162 
T. spiralis larvae were removed prior to culturing. In addition, to ensure a low level of 163 
parasite death, larvae were cultured for 24 h only, before supernatant was collected for 164 
SP purification. 165 
  166 
One Ub enzyme match was made to a putative protein: ‘ubiquitin-conjugating enzyme 167 
E2 L3 (fragment)’. This sequence is annotated as an incomplete open reading frame 168 
(ORF) for a UBE2L3 ortholog (UniProt E5S8T6/GI:339240047/ T.sp_00154). UBE2L3, 169 
also known as UbcH7, E2-F1, UbcM4, L-UBC and UBCE7, is a UBCc domain Ub 170 
conjugating enzyme (Moynihan et al., 1999; Nuber et al., 1996). The annotated fragment 171 
ORF for TsUBE2L3 in the database is 145 amino acids in length and lacks a start codon. 172 
The UBCc domain of the putative TsUBE2L3 spans the fragment from the first amino 173 
acid to the 140th amino acid. Peptides matching TsUBE2L3 were found in the segment 174 
of the gel annotated in Figure 1B, corresponding to its predicted size of 17kDa. 175 
TsUBE2L3 was predicted to have no signal peptide (signalP, iPSORT), and to be 176 
located primarily in the cytoplasm with trace amounts in peroxisomes, nucleus and 177 
extracellular space (WolfPSORT scores of 23, 3, 2 and 2, respectively)[26–28]. All 178 
protein matches labeled as ‘uncharacterized’ were further analyzed using BLAST and 179 
SMART, and no other Ub enzyme domains were identified. 180 
  181 
TsUBE2L3 is responsible for the Ub conjugation activity in T. spiralis SP 182 
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The putative T. spiralis UBE2L3 sequence contains 62.3% of the same residues as the 183 
human UBE2L3. A commercially available antibody raised against a region of the human 184 
enzyme with high identity to the T. spiralis protein was used to analyze T. spiralis SP by 185 
immuno-blot for the presence of UBE2L3. Lysate of T. spiralis muscle larvae and human 186 
HEK 293T cells were also analyzed as positive controls (Figure 2A). In HEK 293T lysate 187 
one prominent band was observed, corresponding to the predicted size of the human 188 
UBE2L3 isoform 1, which is 17.9 kDa in size[29]. In the lysate of T. spiralis muscle 189 
larvae, two prominent bands between 15 and 25 kDa were observed. In the T. spiralis 190 
SP, the most prominent band was observed between 15 and 25 kDa, matching the 191 
smaller band in the T. spiralis lysate, and the only band in HEK 293T lysate. To test for 192 
contaminant proteins released from dead or dying larvae, the samples were reacted with 193 
anti-tubulin antibodies. Although present in the T. spiralis and human cell lysates, tubulin 194 
was not detected in T. spiralis SP by immuno-blot or by proteomic analyses of T. spiralis 195 
SP. 196 
  197 
In order to determine the contribution of TsUBE2L3 to the Ub conjugation activity of T. 198 
spiralis SP, an in vitro depletion assay was carried out (Figure 2B). Using resin-bound 199 
anti-UBE2L3 antibodies, SP were depleted of TsUBE2L3 using the immuno-precipitation 200 
compatible anti-HsUBE2L3 antibodies. As controls, T. spiralis SP were depleted using 201 
resin-bound BSA and resin-bound anti-tubulin antibodies. Depleted SP samples were 202 
then reacted with human parkin in an in vitro Ub conjugation assay whereby parkin auto-203 
ubiquitination was analyzed by streptavidin blot. Reduced signal representing Ub 204 
conjugation activity was generated by the TsUBE2L3-depleted SP compared to the BSA 205 
and anti-tubulin-depleted SP, although signal was not fully depleted due to affinity 206 
inefficiency of the antibody. When quantified this amounted to 61% of the total signal 207 
from the anti-HsUBE2L3 sample indicating a 3rd of the E2 activity having been depleted 208 
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(Figure 2C). Signal was also present in the SP proteins that were eluted from the anti-209 
HsUBE2L3 resin, amounting to the remaining 31% of the total sample signal. Very faint 210 
signal was observed in the proteins eluted from the BSA or tubulin resin that (at 11 and 211 
12% of the total, respectively) could indicate background or non-specific binding to the 212 
resin. Results show that TsUBE2L3 is responsible for at least a 3rd of the Ub conjugation 213 
activity observed in T. spiralis SP (Figure 1A). 214 
  215 
TsUBE2L3 specifically localizes to the T. spiralis secretory organ during 216 
intracellular-stage infection 217 
In order to analyze TsUBE2L3 expression within infected rat skeletal muscle cells (nurse 218 
cells) in situ, an antibody was developed that could not cross-react with mammalian 219 
UBE2L3. Using structural modeling of TsUBE2L3, an N-terminal peptide showing low 220 
homology to the corresponding region of the mammalian ortholog 221 
(QWRGLLLPDKEPYC) was synthesized and used to raise a TsUBE2L3-specific 222 
antibody (Figure 2D). To confirm T. spiralis-specific reactivity, and absence of 223 
mammalian cross-reactivity, anti-TsUBE2L3 was reacted with T. spiralis lysate, T. 224 
spiralis SP and rat (rattus norvegicus-R.n) skeletal muscle tissue (SMT) lysate. Signal at 225 
the expected size between 15 and 25 kDa was observed in the T. spiralis samples, but 226 
not in the R.nSMT lysate. Histological sections of infected rat skeletal muscle tissue 227 
were prepared for immuno-histofluorescence (IHF) analyses using anti-TsUBE2L3 228 
(Figure 2E). Sections were reacted with either anti-TsUBE2L3 or PBS and analyzed by 229 
confocal microscopy in order to locate TsUBE2L3 within the nurse cell complex. 230 
TsUBE2L3 was clearly and specifically localized to condensed, discrete stacks of 231 
secretory cells (stichocytes) inside the secretory organ (stichosome) of each T. spiralis 232 
larva within nurse cells (Figure 2E and F). 233 
  234 
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TsUBE2L3 stably expresses in mouse skeletal myotubes and specifically interacts 235 
with the mammalian E3 ARIH2 236 
In order to identify potential TsUBE2L3-protein interactions in skeletal muscle cells, 237 
transgenic mouse muscle cell (C2C12) lines were generated[30,31]. Since T. spiralis 238 
infects fully differentiated skeletal muscle cells, it was important to investigate the effects 239 
of TsUBE2L3 on myotubes (rather than myoblasts) in culture. The full ORF of 240 
TsUBE2L3 was confirmed by RACE-PCR analysis (Figure S1, 2 and 3) and cloned with 241 
a hemagglutinin epitope tag into a lentiviral vector, facilitating doxycycline (DOX)-242 
controlled, inducible transgene expression. C2C12 myoblasts were lentivirally 243 
transduced with TsUBE2L3-HA, followed by drug selection to create a silent but stable 244 
myoblast cell line. In parallel, control transgenic myoblast lines were developed: 1) an 245 
empty vector, 2) eGFP-HA, for overexpression of an unrelated protein, and 3) 246 
MmUBE2L3-HA, for overexpression of the mouse UBE2L3 ortholog under the same 247 
promoter. All cell lines were differentiated into myotubes (Figure 3A) before transgene 248 
expression was induced (Figure 3B). TsUBE2L3-HA expression was confirmed by anti-249 
HA immuno-fluorescence (IFA) (Figure 3C) and immuno-blot (IB) after 24 hours (h) of 250 
transgene expression (Figure 3D). Reactivity representing TsUBE2L3-HA was observed 251 
at the expected size of approximately 17 kDa at 18, 22 and 48 h post-DOX induction, but 252 
not before DOX induction (0 h). No reactivity was observed in the empty vector control. 253 
IFA analysis also confirmed that in myotubes, TsUBE2L3-HA is cytoplasmic but not 254 
nuclear, despite being observed in both the cytoplasm and nucleus of undifferentiated 255 
myoblasts (Figure S4). Myotubes expressing TsUBE2L3-HA did not appear 256 
morphologically distinct from the empty vector myotubes (Figure S5). 257 
Using anti-HA antibodies, co-immuno-precipitation (IP) from myotubes of all four 258 
transgenic cell lines (empty vector, eGFP-HA, TsUBE2L3-HA and MmUBE2L3-HA) was 259 
carried out after 24 h of transgene expression. Proteins that co-precipitated with the HA-260 
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tagged bait protein were separated by SDS-PAGE, visualized by silver staining, anti-HA 261 
IB (Figure 4A) and analyzed by LC/MS/MS. Data was then searched against the mouse 262 
(Mus musculus) UniProt proteome, its reverse complement and common contaminants. 263 
To validate the data, the experiment was repeated and the two datasets were merged. 264 
All proteins co-precipitated from each cell line were cross-referenced. Amongst these, 265 
six RING E3 enzymes were identified in the TsUBE2L3 sample, ARIH1, ARIH2, TRIM3, 266 
TRIM25, TRIM47 and TRAF7 and one HECT E3, NEDD4 (Figure 4B, Table 1 and Table 267 
S1). As validation for successful TsUBE2L3-specific co-IP, expected “reference” proteins 268 
were also identified including the bait protein sequence itself (TsUBE2L3), and the 269 
mouse UBE1A (Table S1). All E3 proteins that co-precipitated with TsUBE2L3-HA (as 270 
well as controls) and all proteins that only co-precipitated with TsUBE2L3-HA (and 271 
neither control) can be found in Table S2. 272 
  273 
To further investigate the potential for TsUBE2L3 to interact with human E3-RING 274 
proteins, a targeted yeast-2-hybrid (Y2H) interaction screen was performed against a 275 
collection of 166 human E3-RING proteins (including one HECT domain ligase 276 
E6AP/UBE3A) as previously described (Figure S6 and Table S1)[32,33]. This analysis 277 
identified a range of potential TsUBE2L3 interaction partners, observed under low or 278 
high stringency conditions (Figure 4B and Table 1). Interactions detected by His3 279 
selection only represent weaker or more transient interactions, while partners detected 280 
under combined His3/Ade2 selection represent potentially stronger binary interactions. 281 
Notably, a significant proportion of strong, binary interactions were made with members 282 
of the non-canonical RING-between-RING (RBR) ligase family (5 out of 13). As the 283 
interaction between TsUBE2L3 and the human ARIH2 E3-RBR ligase (also known as 284 
ARI1, TRIAD1, Ariadne homologue 2 and All-Trans Retinoic Acid Inducible RING Finger) 285 
was detected in both Y2H and co-IP studies, and was the most abundant E3 to co-286 
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precipitate specifically with TsUBE2L3 (Table S2), this high confidence binary complex 287 
was therefore selected for further functional characterization. 288 
  289 
TsUBE2L3 interacts with RBR ligases with higher affinity than mammalian 290 
orthologs 291 
 Recombinant 6His-HsARIH2ΔAri (lacking the auto-inhibitory Ariadne domain) and 6His-292 
TsUBE2L3 (Figure 5A and C) were individually expressed, purified and used for in vitro 293 
auto-ubiquitination assays. Recombinant 6His-TsUBE2L3 Ub conjugation activity was 294 
validated using human parkin (Figure 5B). Interestingly, when reacted at the same 295 
concentrations, TsUBE2L3 showed a preference (over human UBE2L3) to catalyze 296 
lower forms of parkin-Ub (i.e. mono- and di-Ub) and to lead to more overall Ub 297 
conjugation of ARIH2 of which the majority was also observed to be lower form 298 
ubiquitination (Figure 5B and D). This ubiquitination pattern coupled with the selective 299 
co-precipitation of ARIH2 with TsUBE2L3 led us to speculate that the worm E2 may bind 300 
ARIH2 (and possibly other RBR ligases) with a higher affinity than the mammalian 301 
ortholog. To test this hypothesis, we generated structural models to investigate the 302 
binding affinity of ARIH2 to both TsUBE2L3 and HsUBE2L3. 303 
  304 
Modeling the interactions between TsUBE2L3 and HsUBE2L3 with HsARIH2 and Ub 305 
revealed differences in residues across the respective interfaces. While TsUBE2L3 306 
shares 67% sequence identity to the human HsUBE2L3, within 5 Å of the >450 Å2 307 
interface with HsARIH2, all residues except for two are conserved (83% identity) (Figure 308 
5E). However, overall small global changes between the TsUBE2L3 and HsUBE2L3 309 
sequences and structures (r.m.s.d of 0.5 Å) lead to the formation of additional inter-310 
molecular hydrophobic interactions. In addition, Thr2 of TsUBE2L3 is able to make 311 
significant interactions with Val144 of HsARIH2, not made by Ala2 of HsUBE2L3. This is 312 
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interesting, as mutation of the corresponding residue in HsARIH1 (Ile188) has been 313 
shown to abolish interaction with UBE2L3[34]. These observations were consistent with 314 
predictions by PISA[35] and mCSM-PPI[36] that HsARIH2 would bind to TsUBE2L3 with 315 
higher affinity than HsUBE2L3, with a difference in predicted Gibb's Free Energy of 316 
binding of over 1 kCal/mol. By contrast, the larger interface between TsUBE2L3 and 317 
HsUBE2L3 with Ub (>900 Å) is less well conserved, with only 58% identity of residues 318 
with 5 Å of the interface. Despite this, overall numbers and types of interactions were 319 
consistent between the models, with PISA and mCSM-PPI predicting that they would 320 
bind Ub with similar binding affinities (difference in predicted Gibb's free energy of 321 
binding 0.1 kCal/mol). 322 
  323 
Expression of TsUBE2L3 in skeletal muscle cells leads to a downregulation of 324 
ubiquitination, markedly of motor, sarcomere and ECM proteins 325 
In order to assess the global effect of TsUBE2L3 on C2C12 myotubes, a ubiquitome 326 
analysis was carried out using a post-translational modification (PTM) UbiScan (Ub 327 
remnant proteomics) method[37,38]. This method employs the K-ε-GG antibody that 328 
binds to the di-Gly motif that remains on a ubiquitinated residue of a trypsin-digested 329 
protein (a Ub remnant peptide). This allows enrichment of ubiquitinated peptides from a 330 
whole cell lysate for LC/MS/MS analysis. Transgene expression was induced in all four 331 
mouse myotube cell lines (empty vector, eGFP, TsUBE2L3 and MmUBE2L3) for 24 h 332 
before myotubes were harvested for analysis. Searches were performed against the 333 
mouse UniProt proteome and peptide matches were quantified and normalized. To 334 
calculate fold change, the abundance and strength of each protein match in a particular 335 
sample (eGFP, TsUBE2L3 and MmUBE2L3) was compared to the control sample 336 
(empty vector). Results for all three cell lines were filtered to contain only those with a 337 
significant fold change of 2.5 or above in response to TsUBE2L3, with a maximum 338 
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intensity of 200,000 or above and a maximum % CV of 49.9 or below. Results were 339 
categorized based on annotated biological ontology for further analysis (Figure 6A and 340 
Table S3). The data was screened for changes in ubiquitination of any of the known 341 
mammalian substrates of all strong Y2H E3 partners or E3s that were identified by co-IP 342 
(whether known interactors of UBE2L3 or not). None were identified, suggesting an 343 
alternate role of TsUBE2L3 to that of its host ortholog. 344 
  345 
The ontological group that, overall, displayed the largest specific fold-change in 346 
response to TsUBE2L3 expression was composed of proteins known to play a role in 347 
motility/contraction, sarcomere structure, extracellular matrix (ECM) and cytoskeleton 348 
such as myosin, myomesin, nebulin and troponin. Notably, the majority of proteins that 349 
displayed a significant change in ubiquitination in response the TsUBE2L3 expression 350 
showed a negative fold-change, i.e. in the TsUBE2L3 column of the heatmap (Figure 351 
6A) fewer ubiquitinated forms of the proteins are observed. This suggests that in the 352 
presence of TsUBE2L3, they were either deubiquitinated or not ubiquitinated to begin 353 
with (stabilized). We therefore hypothesized that the consequence of this would be 354 
observed as a reduction in ubiquitination and a resulting increase in abundance. No 355 
significant difference could be observed in the total amount of ubiquitinated protein in 356 
TsUBE2L3 cells compared to empty vector myotubes as measured by pull-down of 357 
polyubiquitinated proteins using tandem ubiquitin binding motif entity resin (TUBE2, 358 
Figure S7A and B). However an increase in the abundance of native myosin II (MYH2) in 359 
the TsUBE2L3 myotubes (the protein that showed the largest fold change in 360 
ubiquitination specifically in response to TsUBE2L3 expression) was observed by 361 
immuno-blot in relation to empty vector cells (Figure 6B and Table S3). This indicates 362 
that there is either a reduction in Ub-mediated proteasomal degradation or an increase 363 
in expression of particular proteins that remain unaffected in empty vector or 364 
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MmUBE2L3 myotubes. Despite an apparent stabilization of proteins important to 365 
sarcomere structure, the overall organization of the myotube sarcomere appeared to be 366 
disrupted by TsUBE2L3 expression (compared to wild-type, empty vector or MmUBE2L3 367 
myotubes). An IFA assay of the sarcomere Z-disc protein α-actinin, shows a larger 368 
proportion of TsUBE2L3 cell structures appearing to be disordered and without 369 
characteristic myotube α-actinin-positive stripes. Although quantification is not 370 
statistically significant, there appears to be a definite trend of fewer α-actinin-positive 371 
stripes in the TsUBE2L3 sample as compared to controls (Figure S7C and D). 372 
  373 
Discussion 374 
Various pathogenic viral and bacterial effectors have been identified and characterized 375 
as Ub-specific enzymes that successfully manipulate the Ub pathway of the host during 376 
infection. Studies in parasites have largely focused on endogenous Ub system 377 
components that are important or essential for parasite biology[39–42]). Although these 378 
studies demonstrate potential for the identification of novel targets for therapeutic 379 
agents, the study of the role of the Ub pathway at the host-parasite interface remains 380 
largely uncharted territory. During this study we used T. spiralis as an effective model to 381 
investigate whether there is a role for the Ub pathway in host-parasite interactions. We 382 
identified the first parasite-derived, host-targeted E2 enzyme, TsUBE2L3, setting 383 
precedence for the further investigation of the role of parasite Ub conjugation enzymes 384 
and the Ub pathway in direct host-parasite interactions. E3 activity was also identified in 385 
T. spiralis SP, although the identity of the proteins responsible could not be elucidated 386 
from conventional LC/MS/MS using the annotated T. spiralis proteome. We are currently 387 
carrying out further analyses to isolate this activity and identify the protein(s) 388 
responsible. 389 
  390 
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TsUBE2L3 is stored in the secretory organ of T. spiralis and is released as an active 391 
enzyme by muscle-stage (L1) larvae. In isolated T. spiralis SP, the E1, E3 and/or the 392 
substrates required for Ub conjugation by TsUBE2L3 are not present, suggesting that 393 
this enzyme requires partner components of the Ub conjugation cascade to be provided 394 
by an external source. We therefore hypothesized that only when in contact with host 395 
partner proteins (i.e. host E3s) does secreted TsUBE2L3 carry out its intended function 396 
as an E2 enzyme. As validation of this hypothesis, a number of potential mammalian E3 397 
ligase partners for TsUBE2L3 were identified. The strongest interaction identified was 398 
with the RBR ligase ARIH2. Very little is known about the function of RBR ligases such 399 
as ARIH2, and to date only one Ub substrate of ARIH2 has been reported in dendritic 400 
cells, the NF-κB inhibitor IκBβ[43]. Although human ARIH2 and UBE2L3 are known to 401 
interact, ARIH2 was not identified by co-IP as a partner for the mouse UBE2L3 ortholog 402 
in skeletal myotubes. When reacted with human parkin in vitro, TsUBE2L3 was 403 
observed to catalyze more mono-Ub-parkin than the human UBE2L3. When reacted with 404 
human ARIH2 in vitro, although both E2s showed a preference for lower Ub forms (over 405 
poly-Ub forms) of ARIH2-Ub, TsUBE2L3 used at the same concentration was observed 406 
to catalyze overall more ubiquitination than HsUBE2L3.  407 
  408 
The current accepted mechanism of RBR-mediated Ub conjugation suggests that a Ub-409 
charged E2 binds to the RING1 domain, Ub is then passed on to the RING2 domain, 410 
and then onto the substrate. The E2 must then dissociate to allow a new Ub-charged E2 411 
to bind to catalyze any subsequent Ub conjugation that would lead to either Ub chain 412 
formation or substrate exchange[44]. Therefore, we postulate that if an E2 binds an RBR 413 
more tightly, formation of mono-Ub or lower forms of Ub would be promoted due to the 414 
slower dissociation of E2 from E3, i.e. the substrate would be more likely to 415 
dissociate/exchange before the E2. Furthermore, the sequestration of the E3 by the E2, 416 
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could lead to an overall reduction in activity of the E3. It was therefore hypothesized that 417 
in our myotube system the parasite TsUBE2L3 has a higher affinity for ARIH2 than the 418 
mouse ortholog[45]. The structural modeling results indeed agreed with this hypothesis, 419 
showing that the T. spiralis E2 makes a more extensive hydrophobic interface with the 420 
E3, leading to tighter binding quantified at approximately 1 kCal/mol difference in binding 421 
affinities between the human and parasite E2s. It is therefore possible that the parasite 422 
UBE2L3 has evolved a higher affinity than the host UBE2L3 in order to outcompete the 423 
endogenous enzyme in nurse cells and sequester the host E3 in an inhibitory manner. 424 
  425 
On a cellular level, TsUBE2L3 expression in C2C12 myotubes caused a significant 426 
downregulation of ubiquitination of motor, sarcomere and ECM-specific proteins; most 427 
notably an effect not observed in response to the expression of the mammalian ortholog.  428 
Although this presented as an increase (stabilization) in the abundance of native form of 429 
myosin II (MYH2 - the protein with the largest significant fold change in response to 430 
TsUBE2L3 expression), the mechanism and physiological effect of this stabilization is 431 
yet to be determined. The remodeling of mammalian skeletal muscle tissue is highly 432 
regulated by ubiquitination[46–48]. In addition, nurse cell development during T. spiralis 433 
infection of muscle cells involves dramatic remodeling of the myofibril[49]. Despite 434 
previous ultrastructural and biochemical evidence suggesting destruction of myofibrillar 435 
proteins in the infected myotube [16,50], the process of nurse cell maintenance is likely 436 
very complex. As such, a role for stabilization may be necessary, particularly at later 437 
stages of nurse cell development where the L1-stage worm is creating a stable “hideout” 438 
within the host cell. Indeed if the regulation of the abundance of the proteins that 439 
comprise the sarcomere is essential for proper sarcomere formation, then a significant 440 
upregulation in abundance due to a reduction in ubiquitin-mediated turnover may lead to 441 
structure disruption as was observed by IFA. Two muscle specific E3 ligases known to 442 
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be upregulated during muscle remodeling and wasting are Murf1 and atrogin-1. These 443 
ubiquitinate structural and motor proteins that are subsequently degraded by the 444 
proteasome[51–53]. An interaction between TsUBE2L3 and Murf1 is unlikely given that 445 
the mammalian UBE2L3 cannot not interact with Murf1, therefore the loss of myofibrillar 446 
proteins seen in previous studies of nurse cells is unlikely to be an effect resulting from 447 
TsUBE2L3. 448 
  449 
Since TsUBE2L3 is an E2, it was initially surprising to observe less overall ubiquitination 450 
in C2C12 cells expressing the parasite protein. However if the mechanism of interaction 451 
of TsUBE2L3 with all host E3 partners is the same as that observed with ARIH2 (namely 452 
to bind more tightly than and outcompete the host E2), then inhibitory E3 sequestration 453 
may play a role in an overall reduction in ubiquitination of target proteins. It is also 454 
possible that TsUBE2L3 acts upstream of a different ubiquitination cascade, perhaps 455 
targeting another E2 or E3 as a substrate for degradation that would ordinarily 456 
ubiquitinate these proteins. It must be noted that studying the effect of TsUBE2L3 on 457 
intact myotubes as opposed to already transformed (T. spiralis-infected) cells may not 458 
reflect its true biological role during infection or relevant stage during nurse cell 459 
formation. The only way to fully assess this would be to generate TsUBE2L3 knock-out 460 
parasites, a process that is currently technically impossible until T. spiralis is rendered 461 
genetically tractable. 462 
  463 
Despite a high level of sequence identity, TsUBE2L3 appears to have evolved a different 464 
binding behavior and cellular function to its host ortholog. Functional divergence of 465 
orthologous proteins is commonly observed to have evolved between non-pathogenic 466 
and pathogenic species of the same lineage, and during specialization of the same 467 
pathogen to different hosts[54–56]. The evolution of worm genomes to species-specific 468 
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parasitism has also been reported[57]. It is therefore possible that this E2 of the zoonotic 469 
T. spiralis parasite evolved under pressure to compete with a host ortholog whose 470 
identity is highly conserved across a wide range of mammalian species. In summary, we 471 
have discovered a novel effect of TsUBE2L3 on skeletal muscle tissue, namely that it 472 
suppresses ubiquitination and degradation of skeletal muscle specific proteins, thus 473 
having a stabilizing effect. Muscular degenerative diseases often involve the loss of 474 
muscle mass, structure and function as a result of the breakdown of proteins such as 475 
myosins. The Ub/proteasome system plays a key role in this pathology[58,59]. Since 476 
treatment of these disorders could involve the stabilization of these degradative 477 
pathways, we are led to speculate on the therapeutic potential of TsUBE2L3. Most 478 
parasitic worm-derived therapeutics are products involved in immuno-regulation, since 479 
many of these parasites have been found to skew the mammalian immune response 480 
towards one that is beneficial in allergic and autoimmune disorders[60–62]. However 481 
there are some parasite-derived mammalian cell modulators whose (non-immuno) 482 
activity is also being investigated for medical purposes[63]. Given the chronic infections 483 
many parasites establish and their specialized tissue tropism within the host, a better 484 
understanding of their cell biology could yield insight into novel treatments for unrelated, 485 
non-infectious diseases.  486 
  487 
 488 
  489 
Experimental procedures 490 
  491 
For detailed experimental methods and primer sequences please refer to 492 
Supplemental Experimental Procedures 493 
  494 
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Collection and analysis of T.spiralis secreted proteins 495 
T. spiralis L1-stage muscle larvae were isolated from infected rat skeletal muscle tissue 496 
(Sprague-Dawley, Harlan UK LTD, Bicester OX25 1TP) by digestion with acidified 497 
pepsin and secreted products (SP) were collected as described by Arden et al[64]. 498 
Protein concentrations were normalized by BCA assay (Pierce) and either separated by 499 
SDS-PAGE and manually extracted from the gel or precipitated by trichloroacetic acid 500 
using standard methods. 501 
  502 
LC/MS/MS 503 
Samples were digested with trypsin using standard protocols and peptides were 504 
analyzed on either an Orbitrap XL2 (T. spiralis SP) or Elite (co-IP) mass spectrometer. 505 
MS2 spectra were searched using SEQUEST v.28 against a composite database 506 
derived from the UniProt Trichinella spiralis proteome, its reversed complement and 507 
known contaminants. Peptide spectral matches were filtered to either a 1% (T. spiralis 508 
SP) false discovery rate (FDR) or a 1.7% FDR (co-IP) using the target-decoy strategy 509 
combined with linear discriminant analysis. 510 
  511 
TsUBE2L3 depletion and Ub conjugation assays 512 
T. spiralis SP were depleted of TsUBE2L3 by incubating with Dynabead-bound (Life 513 
Technologies)-anti-HsUBE2L3 antibodies. Bound proteins were eluted with glycine 514 
elution and refolded into Ub assay buffer. For parkin auto-ubiquitination assays, 515 
reactions were initiated using the Boston Biochem K105 kit according to the 516 
manufacturer’s instructions and p-parkin (kindly donated by Wade Harper and Alban 517 
Ordureau, Harvard Medical School)[65]. Reaction mixtures were initiated by addition of 518 
biotin-Ub:Ub and incubated at 37°C for 1.5 h. Proteins were separated by SDS-PAGE 519 
and analyzed by streptavidin-blot. 520 
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  521 
Generation and differentiation of C2C12 cell lines 522 
PLVX Tet On (1 ml) and pLVX Tight Puro lentivirus particles were prepared in HEK 293T 523 
cells (ATCC) as described by Mostoslavsky et al[66]. Stable transgenic C2C12 (ATCC) 524 
cell lines were generated by spinfection using equal volumes of Tet On and Tight Puro 525 
particles added with 8 µg/ml Polybrene (Sigma) to cells  at 70% confluency. Stable 526 
C2C12 cell lines were drug selected and differentiated into myotubes before transgene 527 
induction using 2 µg/ml doxycycline (DOX). 528 
  529 
Preparation of myotube lysates and co-immuno-precipitation 530 
Nuclear and cytosolic extracts were prepared using the CelLyic NuCLEAR Extraction kit 531 
(Sigma-Aldrich) according to the manufacturer’s instructions. The cytosolic and nuclear 532 
fractions of each sample were pooled and protein concentrations normalized by BCA 533 
assay. Proteins were immunoprecipitated using anti-HA affinity matrix (Roche) and HA 534 
peptide elution. Supernatants were pooled for SDS-PAGE, silver staining and 535 
LC/MS/MS analysis. 536 
  537 
Yeast-2-hybrid (Y2H) analysis 538 
Human E3-RING prey clones were constructed as described previously[32,33] using 539 
pACTBD/E-B vectors[67]. The TsUBE2L3 open reading frame was cloned from 540 
pGEMTeasy into the bait pGBAE-B Y2H vector through in vivo gap repair cloning as 541 
previously described[67,68]. The TsUBE2L3 bait clone was mated against arrays of 166 542 
full-length CDS human E3-RING prey clones and 39 prey clones containing the 543 
cytoplasmic domains of human transmembrane E3-RING proteins. Growth of positive 544 
colonies was monitored and scored over a period of 14 days (Figure S6 and Table S1). 545 
  546 
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UbiScan: LC/MS/MS 547 
UbiScan analysis was carried out by Cell Signaling Technology as previously 548 
described[69–71] and LC/MS/MS was carried out on enriched trypsin-digested Ub 549 
peptides. MS/MS spectra were evaluated using SEQUEST and the Core platform from 550 
Harvard University[37,38,72]. Searches were performed against the most recent update 551 
of the NCBI Mus musculus database with mass accuracy of +/-5 ppm for precursor ions 552 
and 1 Da for product ions. Results were filtered for the presence of the intended motif 553 
(K-εGG). 554 
  555 
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Figure and Table legends: 764 
  765 
Figure 1. Identification of E2 and E3 activity in T. spiralis SP. A. Streptavidin-HRP blot of 766 
in vitro ubiquitination reactions including 1) human E1 (UBE1A), E2 (UBE2L3), E3 767 
(parkin), and Ub-biotin, 2) in the absence of the E2, 3) SP substituted for the human E2, 768 
4) SP substituted for the human E3, 5) SP substituted for the human E1, 6) SP 769 
substituted for both the human E2 and E3, 7) SP and Ub-biotin alone. B. T.sp SP were 770 
separated by SDS-PAGE and visualized by silver-staining. 50 µg of SP were de-771 
glycosylated by PNGase treatment and analyzed by LC/MS/MS (10 µg of glycosylated 772 
proteins were analyzed for comparison). Peptides matching a T. spiralis E2, TsUBE2L3, 773 
were identified from the boxed section of the gel. 774 
  775 
Figure 2. Verification of expression, secretion, activity and localization of TsUBE2L3. A. 776 
T.sp SP, HEK 293T cell lysate and T. spiralis muscle larvae lysate were separated by 777 
SDS-PAGE and immuno-blotted with anti-HsUBE2L3 and anti-tubulin antibodies . B. 778 
Auto-ubiquitination of parkin with Ub-biotin was probed by streptavidin-HRP blot. 779 
Reactions from left to right: lane 1: human E1 (UBE1A), E3 (parkin) and Ub-biotin only 780 
(no E2). Reactions in lanes 2-4 included human E1, parkin and Ub-biotin, with the 781 
following E2 substitution: lane 2: T.sp SP after resin-bound BSA depletion (BSA), lane 3: 782 
T.sp SP after resin-bound anti-tubulin depletion (α-tubulin), lane 4: T.sp SP after resin-783 
bound α-HsUBE2L3 depletion (α-HsUBE2L3). In lanes 5-7 the elution fractions from the 784 
depletions shown in lanes 2-4 were used to substitute E2. C. The pixel intensity of lanes 785 
2-7 of the depletion assay (B) was analysed using an ImageJ gel analysis plugin. For 786 
each of the three samples tested in the assay (BSA, α-tubulin and α-HsUBE2L3) the 787 
sum of the pixel intensity of the depletion plus elution lanes was taken as 100% 788 
(intensity of lane 2 + 5 for BSA and so on). The relative percentages of the depletion and 789 
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elution lanes were then calculated (intensity of lane 2/(2+5) x 100) and plotted. D. A 790 
TsUBE2L3-specific antibody was made and its specificity was assessed by immuno-blot 791 
against T.sp L1 lysate, T.sp SP and rat (R.n) skeletal muscle tissue (SMT) lysate. The 792 
arrow indicates the expected size of TsUBE2L3. E. T. spiralis infected rat skeletal 793 
muscle tissue (R.n SMT) was sectioned and analyzed by immuno-histofluorescence . A 794 
single T.sp L1 inside the nurse cell (n), surrounded by a collagen capsule (c) is 795 
displayed. Tissue was probed with anti-TsUBE2L3 antibodies (Alexa-568, red) and 796 
nuclei were stained using DAPI (blue). Brightfield (BF)/DAPI/anti-TsUBE2L3 and 797 
DAPI/anti-TsUBE2L3 merged images are displayed.  As a control, infected R.nSMT was 798 
probed with PBS and DAPI only. Arrows indicate stacks of stichocyte cells in the 799 
stichosome. F. Annotated diagram of T. spiralis L1 morphology. Image adapted from a 800 
drawing by Villella, J.B. (1970, Life cycle and morphology, in: Trichinosis in Man and 801 
Animals (S.E. Gould, ed.), Charles C. Thomas, Springfield, Illinois, pp. 19-60,) taken 802 
from Trichinella.org/biology. 803 
  804 
Figure 3. Development of expression system for TsUBE2L3 analysis in C2C12 805 
myotubes. A. Wild-type C2C12 undifferentiated myoblasts and terminally differentiated 806 
myotubes were probed by immuno-fluorescence (IFA) with anti-tubulin antibodies 807 
(Alexa-488, green) and nuclei were stained with DAPI (blue). B. Schematic of the pLVX 808 
expression construct containing the coding sequence for TsUBE2L3-HA, showing the 809 
mechanism of induction by doxycycline (DOX). C. Myotubes transduced with empty 810 
vector pLVX or TsUBE2L3-HA pLVX and induced with DOX for 24 h were probed by IFA 811 
with anti-HA antibodies (Alexa-568, red); nuclei were stained with DAPI (blue). D. Empty 812 
vector and TsUBE2L3-HA cell lysates were reacted with myogenic differentiation 813 
markers, myogenin and myosin heavy chain II (MHC), and anti-HA antibodies, at 814 
indicated time points after 24 h DOX induction and analyzed by immuno-blot. The same 815 
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samples were probed with anti-tubulin as a loading control. 816 
  817 
Figure 4. Co-immuno-precipitation (co-IP) and yeast-2-hybrid (Y2H) analyses of 818 
TsUBE2L3. A. Transgenic C2C12 myotube lines (empty vector, eGFP-HA, TsUBE2L3-819 
HA and mouse MmUBE2L3-HA) after 24 h DOX induction were probed by co-IP with 820 
anti-HA antibody. Co-IP elutions were silver-stained and all co-IP'd proteins were 821 
analyzed by LC/MS/MS. The same samples were reacted with anti-HA antibodies by 822 
immuno-blot (IB) as a control for transgene expression. B. Protein interaction network 823 
showing positive interactions between TsUBE2L3 and human E3 ligases as observed by 824 
yeast-2-hybrid (Y2H) and co-IP analyses. Key indicates if interactions were found by 825 
Y2H to be strong, weak or by co-IP. 826 
  827 
Table 1. Identification of TsUBE2L3 E3 interaction partners by co-IP and yeast-2-hybrid 828 
(Y2H) analyses. Only interactions measured by Y2H as being strong are listed. Known 829 
ubiquitination substrates found by UbiScan analysis to be significantly and specifically 830 
upregulated (upreg.) or downregulated (downreg.) after expression of TsUBE2L3-HA are 831 
listed. 832 
  833 
Figure 5. Expression, purification and activity of 6His-TsUBE2L3 and 6His-ARIH2 in 834 
vitro.  A. Coommassie stain of 6His-TsUBE2L3 from un-induced (UI) and induced (I) 835 
E.coli cultures, nickel purification resin flow-through (FT1-2), wash (W) and elutions (E1-836 
2). B and D. Streptavidin-HRP blots of in vitro parkin auto-ubiquitination reactions using 837 
human E1 (UBE1A), human Ub-biotin and either no E2, human E2 (HsUBE2L3) or 6His-838 
TsUBE2L3 with (B) human parkin as the E3 or (C) human ARIH2 as the E3. C. 839 
Coomassie stain of 6His-HsARIH2ΔAri from un-induced (UI) E.coli cultures, inclusion 840 
body supernatants (S1-4) induced inclusion bodies (I) and refolded from inclusion bodies 841 
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(Rf). E. Surface representation of ARIH2 (grey) and Ub (wheat) with HsARIH2 (green) 842 
and TsUBE2L3 (cyan) bound to the RING1 domain of ARIH2. Residue differences 843 
between the E2-E3 interfaces are shown as sticks (HsARIH2 in orange and TsUBE2L3 844 
in magenta). Zinc ions are shown as blue spheres, and Val141 of ARIH2 is shown as 845 
sticks. F. Zoom of the ARIH2:E2:Ub interface. 846 
  847 
Figure 6. UbiScan analysis of TsUBE2L3 effect on the myotube ubiquitome. A. 848 
Heatmap displaying proteins in which ubiquitinated peptides were found to be 849 
upregulated (blue) or downregulated (red) as measured by a fold change in relation to 850 
the empty vector C2C12 myotube cell line after 24 h expression of eGFP-HA (GFP), 851 
TsUBE2L3-HA (TsE2) or MmUBE2L3-HA (MmE2). Proteins listed showed a maximum 852 
% CV of 49.9 or less, a maximum intensity of 200,000 or more and a fold change in 853 
ubiquitination of 2.5 or more in response to TsUBE2L3-HA expression only. Where 854 
multiple ubiquitinated peptides were identified for the same protein (according to the 855 
protein description as assigned by Cell Signaling Technology), the mean fold change 856 
was calculated. Proteins were grouped according to annotated biological ontology. B. 857 
Myosin II/fast skeletal myosin (MYH2) (the protein with the largest significant fold change 858 
specifically in response to TsUBE2L3 expression) was analyzed by immuno-blot in the 859 
empty vector and TsUBE2L3 C2C12 myotube cell lines before and after 24 h of 860 
induction (DOX) using anti-myosin II antibodies and anti-vinculin as a loading control. 861 
  862 
Figure S1, related to Figure 1 and 2. Race confirmation of TsUBE2L3 3’ ORF. The 863 
RACE-PCR sequencing data of the 3’ end of TsUBE2L3 cDNA aligned with the 864 
annotated fragment coding sequence that is currently found in the NCBI database. 865 
Figure shows the position of the RACE oligo, the RACE 3’ forward primer-binding site, 866 
the stop site of the full coding sequence of the gene, the custom gene-specific forward 867 
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primer (GSFP)-binding site and the cloning vector (pGEMTeasy) sequences. The 868 
sequence contained a 3’ continuation after the stop codon that was identified as T. 869 
spiralis genomic DNA (gDNA). 870 
  871 
Figure S2, related to Figure 1 and 2. Race confirmation of TsUBE2L3 5’ ORF. The 872 
RACE-PCR sequencing data of the 5’ end of TsUBE2L3 cDNA aligned with the 873 
annotated fragment coding sequence that is currently found in the NCBI database. 874 
Figure shows the position of the RACE oligo, the RACE 5’ forward primer-binding site, 875 
the start site of the full coding sequence of the gene, the custom gene-specific reverse 876 
primer (GSRP)-binding site and the cloning vector (pGEMTeasy) sequence. 877 
  878 
Figure S3, related to Figure 1 and 2. TsUBE2L3 alignments. The annotated fragment 879 
(incomplete) coding sequence (cds) for TsUBE2L3 (GI:339240046/Tsp_00154/UniProt: 880 
E5S8T6 - found in the contig sequence: GI:316975344) that is currently found in the 881 
NCBI database was aligned with the full RACE-PCR confirmed sequence from start to 882 
stop, compiled from both 5’ RACE-PCR and 3’ RACE-PCR data, and with the human 883 
UBE2L3 isoforms #1, #3 and #4 cds’ (GI:4507789, GI:373432682 and GI:373432684 884 
respectively-Uniprot: P68036). 885 
  886 
Figure S4, related to Figure 3. IFA of transgenic TsUBE2L3-HA C2C12 cells. IFA of 887 
transgenic TsUBE2L3-HA C2C12 undifferentiated myoblasts and differentiated 888 
myotubes showing Alexa-488 conjugated anti-HA (green), DAPI-stained nuclei (blue), 889 
brightfield (BF) and overlay (merge of three signals). Row 1 shows myoblasts with 890 
cytoplasmic TsUBE2L3-HA localization in a myoblast. Row 2 shows cytoplasmic and 891 
nuclear TsUBE2L3-HA localization in myoblasts. Row 3 shows only cytoplasmic 892 
TsUBE2L3-HA localization in myotubes. Images are representative of multiple biological 893 
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replicates. 894 
  895 
Figure S5, related to Figure 3. IFA of transgenic (eGFP-HA and TsUBE2L3-HA) 896 
C2C12 cell lines. IFA of anti-tubulin showing no overall morphological/shape change of 897 
cells. 898 
  899 
Figure S6, related to Figure 4. Yeast-2-hybrid (Y2H) raw data. Image of Y2H plates 900 
(all included in screen-positive and negative). Targeted Y2H matrix mating assays 901 
screening TsUBE2L3 against arrays of full length and truncated E3-RING proteins (for 902 
layout see Sup Table 1). Yeast growth indicates positive protein-protein interaction. 0-5 903 
colonies: background yeast growth, 6-20 colonies: weak interaction, 20-200 colonies: 904 
medium interaction, full plaque: strong interaction. Interactions observed only with the 905 
Ade2 reporter (SD-WLA) are not considered true positive interactions, however those 906 
with the His3 reporter only (SD-WLH(AT)) are considered positive. 907 
  908 
Table S1, related to Figure 4 and S4. Yeast-2-hybrid raw plate layout. Layouts of E3-909 
RING prey arrays screened against TsUBE2L3 (see Figure S2). Top and middle panel 910 
contain full-length cds E3-RING prey clones, generated by Markson and Woodsmith et 911 
al[32,33]. Bottom panel contains truncated transmembrane E3-RING prey clones 912 
(transmembrane domains removed), generated by Jenn, R.C (unpublished data). * Non-913 
E3-RING clones in the array. Red text indicates interaction with TsUBE2L3. 914 
  915 
Table S2, related to Figure 4. Co-IP data. Table of co-IP data showing reference 916 
results including the annotated protein sequence that is currently found in the NCBI 917 
database (“ubiquitin-conjugating enzyme E2 L3, partial” GI:339240047), all E3 proteins 918 
that co-IP'd with TsUBE2L3-HA (as well as controls) and all proteins that only co-IP'd 919 
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with TsUBE2L3-HA (and neither control). E3 ligases are highlighted in bold font. 920 
  921 
Table S3, related to Figure 6. Raw UbiScan data. UbiScan data as generated by Cell 922 
Signaling Technology showing fold change by protein type in levels of ubiquitinated 923 
peptides in GFP, TsUBE2L3 and MmUBE2L3 myotubes, in relation to the empty vector 924 
control cell line. 925 
  926 
Figure S7, related to Figure 6. A. TUBE2 IP from transgenic myotube cell lines. 927 
Anti-Ub immuno-blot showing normalized lysates of empty vector and TsUBE2L3 C2C12 928 
myotube cells (input), results of tandem ubiquitin binging entity pull-down (TUBE2), and 929 
unbound protein. An anti-vinculin immuno-blot of the same samples was included as a 930 
loading control. B. Quantification of Ub immuno-blot. ImageJ was used to analyze the 931 
intensity (raw pixel area) of each smear from the immuno-blot shown in A. C. IFA of 932 
transgenic myotube cell lines. IFA of anti-α-actinin/Alexa488 (with DAPI-stained 933 
nuclei) showing fewer ordered sarcomere A-bands in the TsUBE2L3-HA cells than in the 934 
wild-type, empty vector and MmUBE2L3 cells. D. ImageJ quantification (using the 935 
“analyze stripes” plugin) of the number of striped α-actinin-positive structures in each cell 936 
line. The mean number of stripes calculated from the analysis of 7 images (per cell line) 937 
taken over 3 independent experiments is displayed for each cell line, with error bars 938 
representing the standard error of the mean. 939 
 940 
  941 
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Table 1. 942 
# 
Mammalian E3 ligase 
Identification 
method 
E3 
domain 
Known Ub 
substrates 
Human 
UBE2L3 
interaction 
(literature) 
Protein 
name 
Human 
protein ID 
(Uniprot) Gene name(s) 
Y2H 
strong Co-IP 
1 ARIH1 Q9Y4X5 ARIH1, ARI, MOP6, 
UBCH7B, HUSSY-
27, Ariadne-1 
  + RBR E1F4E2 + 
2 ARIH2 O95376 ARIH2, ARI2, 
TRIAD1, HT005, 
Ariadne-2 
+ + RBR IκBβ + 
3 NEDD4 P46934 NEDD4, NEDD4-1   + HECT IGF1R, 
FGFR1, 
TNK2, ebola 
virus VP40 
+ 
4 RNF125 Q96EQ8 RNF125 +   RING p53, p73 + 
5 RNF138 Q8WVD3 RNF138, NARF, 
HSD-4, HSD4 
+   RING TCF/LEF + 
6 RNF14 Q9UBS8 RNF14, ARA54, 
HRIHFB2038 
+   RBR unknown + 
7 RNF144
A 
P50876 RNF144A, 
KIAA0161, RNF144, 
UBCE7IP4 
+   RBR PRKDC + 
8 RNF19
A 
    +   RBR SNCAIP, 
CASR, 
SOD1 
+ 
9 RNF37 O94941 UBOX5, KIAA0860, 
RNF37, UBCE7IP, 
UIP5 
+   RING unknown + 
10 TRAF7 Q6Q0C0  
  
TRAF7, RNF119, 
TNF-Rc associated-
7, RFWD1 
  + RING unknown + 
11 TRIM3 O75382 TRIM3, BERP, 
RNF22, RNF97 
  + RING GKAP/ 
SAPAP1 
  
12 TRIM25 Q14258 TRIM25, EFP, 
RNF147, ZNF147 
  + RING DDX58   
13 TRIM47 Q96LD4 TRIM47, RNF100, 
GOA 
  + RING unknown   
 943 






